Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2‐positive breast cancer: An open‐label, dose‐escalation, phase I study

by Ruoxi Hong, Wen Xia, Liye Wang, Kaping Lee, Qianyi Lu, Kuikui Jiang, Shengfeng Li, Jinquan Yu, Jin Wei, Weijia Tang, Danyang Zhou, Xin An, Jiajia Huang, Cong Xue, Xiwen Bi, Yanxia Shi, Zhongyu Yuan, Fei Xu, Shusen Wang
Published 2021-02-01